MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2025.127819

Медицинская библиотека · Vaccine · 2025

Immunogenicity and safety evaluation of a recombinant protective antigen anthrax vaccine (GC1109): A phase II, dose-confirmed, randomized, double-blind, placebo-controlled study.

Kang Chang Kyung, Im Young Jin, Kim Dah Yoon, Choe Pyoeng Gyun, Baek Yae Jee, Lee Eunjung, Choi Won Suk, Wie Seong-Heon, Seo Yu Bin, Lee Jacob, Kim Nam Joong, Oh Myoung-Don

СтатьяРандомизированное исследованиеКлиническое исследование II фазыПеревод в очереди

Аннотация

BACKGROUND

GC1109, a novel recombinant protective antigen (PA) anthrax vaccine, has demonstrated promising immunogenicity in previous dose-finding trials. This study evaluated the immunogenicity and safety of four intramuscular doses of GC1109 in healthy adults.

METHODS

This randomized, double-blind, placebo-controlled phase 2 trial enrolled healthy volunteers aged 19 to 65 years. Participants were assigned in a 3: 1 ratio to receive either GC1109 (1.0 mL) or placebo at weeks 0, 4, 8, and 32. Immunogenicity was assessed using toxin neutralization antibody (TNA) titers and anti-PA IgG levels. The primary endpoint was the proportion of vaccine recipients achieving a TNA 50 % neutralization factor (NF50) ≥ 0.56 at week 36. Safety was evaluated through solicited and unsolicited adverse events (AEs).

RESULTS

All participants in the GC1109 group achieved TNA NF50 ≥ 0.56 at week 36 (100 %, 95 % confidence interval: 97.6-100.0) and the predefined criterion for the primary endpoint was met. TNA and anti-PA IgG levels peaked at week 36 but declined thereafter. Pruritus was the only solicited AE significantly more frequent in the GC1109 group; serious AEs were rare and unrelated to vaccination.

CONCLUSIONS

Four doses of GC1109 were immunogenic and generally well-tolerated. Further studies are needed to explore appropriate boosting strategies and evaluate safety in larger populations.

Для цитирования: Kang Chang Kyung, Im Young Jin, Kim Dah Yoon, Choe Pyoeng Gyun, Baek Yae Jee, Lee Eunjung, Choi Won Suk, Wie Seong-Heon, Seo Yu Bin, Lee Jacob, Kim Nam Joong, Oh Myoung-Don. Immunogenicity and safety evaluation of a recombinant protective antigen anthrax vaccine (GC1109): A phase II, dose-confirmed, randomized, double-blind, placebo-controlled study.. Vaccine. 2025. DOI: 10.1016/j.vaccine.2025.127819.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.